Aviva Ventures, Aviva plc's venture capital arm, has invested in Owlstone Medical Ltd, a medical diagnostics company developing a breathalyser that can detect diseases at a very early stage.
The company is currently developing tests for lung and colorectal cancer, two of the most common terminal cancer conditions worldwide. Aviva Ventures' investment takes Owlstone Medical's total funding to $23.5 million USD (£19.3 million GBP) since its spin out of Owlstone Inc in 2016. Aviva Ventures provides early stage investment to back entrepreneurs with high growth businesses and, over time, expects to have a portfolio of small investments in a number of companies which have significant potential. Ben Luckett, Managing Director at Aviva Ventures, said: "Our intention is to inv...
To continue reading this article...
Join COVER for free
Signup and gain exclusive members-only insights
- Unlimited access to real-time news, key trend analysis and industry insights.
- Stay on top of the latest developments around health and wellbeing, diversity and inclusion and the cost of living crisis.
- Receive breaking news stories straight to your inbox in the daily newsletter.
- Members only access to monthly programme 'The COVER Review'
- Be the first to hear about our CPD accredited events and awards programmes.
